Financing led by CEO Alon Ben-Noon and CFO Or Eisenberg, alongside participation from an existing significant shareholder

由首席执行官Alon Ben-Noon和首席财务官Or Eisenberg主导的融资，同时现有的一位重要股东也参与其中。

CAMBRIDGE, Mass.

马萨诸塞州剑桥市

,

，

April 28, 2026

2026年4月28日

/PRNewswire/ --

/PRNewswire/ --

NeuroSense Therapeutics Ltd.

神经传感治疗有限公司

(Nasdaq:

（纳斯达克：

NRSN

神经调节蛋白受体（NRSN）

) ('NeuroSense'), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced the entry into a definitive agreement with certain investors to purchase $600,000 of ordinary shares in a private placement. In connection with the offering, NeuroSense agreed to sell an aggregate of 750,000 ordinary shares at a price of $0.80 per share, representing a purchase price of 6.7% above the closing pricing of NeuroSense's ordinary shares on April 27, 2026..

）（'NeuroSense'），一家处于临床后期阶段的生物技术公司，致力于开发治疗严重神经退行性疾病的新型疗法，今天宣布已与某些投资者达成最终协议，以私募方式出售价值60万美元的普通股。根据此次发行，NeuroSense同意以每股0.80美元的价格出售总计75万股普通股，该价格比2026年4月27日NeuroSense普通股的收盘价高出6.7%。

The private placement is subject to customary closing conditions and is expected to close during the week of May 3, 2026.

私募发行需满足惯例的交割条件，预计将于2026年5月3日当周完成。

The private placement included participation from Company insiders and a leading existing shareholder. Chief Executive Officer Alon Ben-Noon, Chief Financial Officer Or Eisenberg, and a significant existing investor each committed $200,000 in the offering.

私募配售包括公司内部人士和一位主要现有股东的参与。首席执行官Alon Ben-Noon、首席财务官Or Eisenberg以及一位重要的现有投资者各自承诺在此次发行中投资20万美元。

The Company intends to use the proceeds for general corporate purposes ahead of upcoming clinical and regulatory milestones.

公司打算将这笔资金用于即将到来的临床和监管里程碑之前的公司一般用途。

The offering is being made in reliance on an exemption from registration under Section 4(a)(2) of the Securities Act and/or Regulation D thereunder. Accordingly, the securities issued in the offering may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws..

本次发行依赖《证券法》第4(a)(2)条和/或据此的D条例的注册豁免进行。因此，除非根据有效的注册声明或适用的《证券法》及相应州证券法的注册要求豁免，本次发行的证券不得在美国境内发售或出售。

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction..

本新闻稿不构成出售要约或购买要约的邀请，也不得在任何州或司法管辖区进行此类证券的销售，如果在该州或司法管辖区，此类要约、邀请或销售在根据其证券法进行注册或资格认证之前是非法的。

About

关于

NeuroSense

神经感知

NeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include amyotrophic lateral sclerosis (ALS), Alzheimer's disease and Parkinson's disease, among others, represent one of the most significant unmet medical needs of our time, with limited effective therapeutic options available for patients to date.

NeuroSense Therapeutics, Ltd. 是一家临床阶段的生物技术公司，专注于为患有严重神经退行性疾病的患者发现和开发治疗方法。NeuroSense 认为，这些疾病包括肌萎缩侧索硬化症（ALS）、阿尔茨海默病和帕金森病等，代表了我们这个时代最重大的未满足医疗需求之一，迄今为止患者的治疗选择非常有限。

Due to the complexity of neurodegenerative diseases and based on strong scientific research on a large panel of related biomarkers, NeuroSense's strategy is to develop combined therapies targeting multiple pathways associated with these diseases..

由于神经退行性疾病的复杂性，并基于对大量相关生物标志物的深入科学研究，NeuroSense 的策略是开发针对这些疾病相关多条通路的联合疗法。

For additional information, we invite you to visit our

有关更多信息，我们邀请您访问我们的网站

website

网站

and follow us on

关注我们

LinkedIn

领英

,

，

YouTube

YouTube

and

和

X

X

. Information that may be important to investors may be routinely posted on our website and these social media channels.

对投资者而言可能重要的信息可能会定期发布在我们的网站和这些社交媒体渠道上。

Forward-Looking Statements

前瞻性声明

This press release contains 'forward-looking statements' that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as 'anticipate,' 'believe,' 'contemplate,' 'could,' 'estimate,' 'expect,' 'intend,' 'seek,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'target,' 'aim,' 'should,' 'will' 'would,' or the negative of these words or other similar expressions, although not all forward-looking statements contain these words.

本新闻稿包含“前瞻性陈述”，这些陈述受到重大风险和不确定性的影响。本新闻稿中除历史事实陈述之外的所有陈述均为前瞻性陈述。本新闻稿中的前瞻性陈述可能通过使用诸如“预期”、“相信”、“考虑”、“可能”、“估计”、“预计”、“意图”、“寻求”、“或许”、“也许”、“计划”、“潜力”、“预测”、“项目”、“目标”、“旨在”、“应该”、“将会”、“会”等词语或这些词语的否定形式或其他类似表达来识别，尽管并非所有前瞻性陈述都包含这些词语。

Forward-looking statements are based on NeuroSense Therapeutics' current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict and include statements regarding the timing of regulatory filings, meetings and regulatory decisions. Further, certain forward-looking statements, including statements regarding the offering, including as to the consummation of the offering described above, the expected gross proceeds from the offering, the intended use of proceeds and the timing of the receipt of proceeds of the offering, are based on assumptions as to future events that may not prove to be accurate.

前瞻性声明基于NeuroSense Therapeutics的当前预期，并受制于难以预测的固有不确定性、风险和假设，其中包括关于监管文件、会议和监管决策时间的声明。此外，某些前瞻性声明，包括有关上述发行的完成、发行的预期总收益、收益的预期用途以及收益到账时间的声明，均基于对未来事件的假设，而这些假设可能被证明不准确。

The future events and trends may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward looking statements. These risks include the uncertainty regarding outcomes and the timing of current and future clinical trials; timing for reporting data, including from the study of PrimeC in Alzheimer's disease; that the study will not be successful; the ability of NeuroSense to remain listed on Nasdaq; and other risks and uncertainti.

未来事件和趋势可能不会发生，实际结果可能与前瞻性陈述中预期或暗示的结果有重大不利差异。这些风险包括对当前和未来临床试验结果及其时间的不确定性；数据报告的时间，包括阿尔茨海默病中PrimeC研究的数据；研究可能不会成功；NeuroSense能否继续在纳斯达克上市；以及其他风险和不确定性。

Logo:

标志：

https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg

https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg

SOURCE NeuroSense

源神经感知

21

21

%

%

more press release views with

更多新闻稿浏览量与

Request a Demo

请求演示